The recent progress in RSV vaccine technology.
The most effective way to control RSV infection would be the development of an expedient and safe vaccine. Subunit vaccines, live attenuated RSV vaccines, plasmid DNA vaccines have been tested either in human or in mouse models without reaching the ultimate goal of efficacy and safety, at least in humans. Viruses such as adenovirus, sendai virus, measles virus were also used as vectors for the generation of RSV vaccines with promising results in animal models. Recent patents describe new techniques for the generation of candidate vaccines. These patents include virus like particles as vaccine platforms, recombinant RSVs or modified RSV F protein as component of the vaccine. Despite the number of the candidate vaccines, the new RSV vaccines should overcome many obstacles before being established as effective vaccines for the control of RSV infections especially for the young infants who are more susceptible to the virus.
3rd Department of Pediatrics, Attikon University Hospital, Athens University, School of Medicine, 1 Rimini str, Haidari, 12462 Athens, Greece.
Andrew
A
Fretzayas
Anna
A
Papadopoulou
Doxa
D
Kotzia
Maria
M
Moustaki
D000818:Animals; D006801:Humans; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000502:physiology
D022261:Respiratory Syncytial Virus Vaccines